Investors in Apogee Enterprises, Inc. APOG need to pay close attention to the stock based on moves in the options market ...
Architectural products company Apogee (NASDAQ:APOG) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but ...
Q1 fiscal 2027. Management View "Our team delivered revenue of $343 million and adjusted diluted EPS of $0.57 in the quarter, dem ...
StockStory.org on MSN
Apogee (APOG) to report earnings tomorrow: Here is what to expect
Architectural products company Apogee (NASDAQ:APOG) will be announcing earnings results this Friday before market hours. Here ...
Detailed price information for Apogee Entrpr Inc (APOG-Q) from The Globe and Mail including charting and trades.
Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.
Definium's Phase 3 LSD trial for depression beats with an 8.1-pt MADRS improvement, sending shares up 30%+ premarket. AbbVie ...
Shares of Apogee Enterprises jumped after the company more than doubled its operating income despite a small decline in sales and swung to a quarterly profit. The stock was up 12% at $47.60 in ...
A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.
Apogee Therapeutics — The biotechnology company soared 50% after AbbVie confirmed it will acquire the company. The $10.9 billion transaction will see AbbVie acquire all outstanding shares of Apogee ...
On June 22, AbbVie announced that it would acquire Apogee Therapeutics (APGE +0.10%), a biotech company focused on developing medicines for immunological and inflammatory diseases. AbbVie will pay ...
The top S&P 500 healthcare gainers and losers for the last week are as follows: Bio-Techne ( TECH) +22.58% AbbVie ( ABBV) +17.03% Charles River Laboratories International ( CRL) +16.62% Incyte ( INCY) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results